Outcomes of pancreas transplants for patients with type 2 diabetes mellitus

Dilip S. Nath, Angelika C Gruessner, Raja Kandaswamy, Rainer W G Gruessner, David E R Sutherland, Abhinav Humar

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Background: The objective of this study was to examine how effectively pancreas transplants provide long-term glucose control in patients with type 2 diabetes mellitus (DM). We used guidelines from the American Diabetes Association (ADA) and the World Health Organization (WHO) to appropriately classify recipients with type 2 DM (vs. type 1 DM). Results: From 1994 through 2002, a total of 17 patients with type 2 DM underwent a pancreas transplant at our center. Mean recipient age was 52.5 yr. The mean age at diabetes onset was 35.7 yr; mean duration, 16.8 yr. Most recipients had one or more secondary complications related to their diabetes: retinopathy (94%), neuropathy (76%), or nephropathy (65%). At the time of their transplant, three (18%) were on oral hypoglycemic agents alone and 14 (82%) were on insulin therapy. Of the 17 transplants, seven (41%) were a simultaneous pancreas-kidney transplant (SPK); four (24%), pancreas after kidney transplant (PAK); and six (35%), pancreas transplant alone (PTA). One recipient died during the perioperative period because of aspiration. The other 16 recipients became euglycemic post-transplant and had a functional graft at 1 yr post-transplant (patient and graft survival rates, 94%). Now, with a mean follow-up of 4.3 yr post-transplant, the patient survival rate is 71%. The four additional deaths were because of sepsis (n = 2), suicide (n = 1), and unknown cause (n = 1). All four of these recipients were insulin-independent at the time of death, although one was on an oral hypoglycemic agent. Of the 12 recipients currently alive, 11 remain euglycemic without requiring insulin therapy or oral hypoglycemic agents; one began insulin therapy 1.2 yr post-transplant (current daily dose, 60 units). Conclusion: These findings suggest that pancreas transplants can provide excellent glucose control in recipients with type 2 DM. All 16 (94%) of our recipients whose transplant was technically successful were rendered euglycemic. Long-term results were comparable with those seen in transplant recipients with type 1 DM.

Original languageEnglish (US)
Pages (from-to)792-797
Number of pages6
JournalClinical Transplantation
Volume19
Issue number6
DOIs
StatePublished - Dec 2005
Externally publishedYes

Fingerprint

Type 2 Diabetes Mellitus
Pancreas
Transplants
Hypoglycemic Agents
Insulin
Type 1 Diabetes Mellitus
Survival Rate
Kidney
Glucose
Perioperative Period
Graft Survival
Age of Onset
Suicide
Sepsis
Therapeutics
Guidelines

Keywords

  • Pancreas transplants
  • Surgical complications
  • Type 2 diabetes mellitus

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Outcomes of pancreas transplants for patients with type 2 diabetes mellitus. / Nath, Dilip S.; Gruessner, Angelika C; Kandaswamy, Raja; Gruessner, Rainer W G; Sutherland, David E R; Humar, Abhinav.

In: Clinical Transplantation, Vol. 19, No. 6, 12.2005, p. 792-797.

Research output: Contribution to journalArticle

Nath, Dilip S. ; Gruessner, Angelika C ; Kandaswamy, Raja ; Gruessner, Rainer W G ; Sutherland, David E R ; Humar, Abhinav. / Outcomes of pancreas transplants for patients with type 2 diabetes mellitus. In: Clinical Transplantation. 2005 ; Vol. 19, No. 6. pp. 792-797.
@article{6c1b5e3087544094b653c9dad0ab7303,
title = "Outcomes of pancreas transplants for patients with type 2 diabetes mellitus",
abstract = "Background: The objective of this study was to examine how effectively pancreas transplants provide long-term glucose control in patients with type 2 diabetes mellitus (DM). We used guidelines from the American Diabetes Association (ADA) and the World Health Organization (WHO) to appropriately classify recipients with type 2 DM (vs. type 1 DM). Results: From 1994 through 2002, a total of 17 patients with type 2 DM underwent a pancreas transplant at our center. Mean recipient age was 52.5 yr. The mean age at diabetes onset was 35.7 yr; mean duration, 16.8 yr. Most recipients had one or more secondary complications related to their diabetes: retinopathy (94{\%}), neuropathy (76{\%}), or nephropathy (65{\%}). At the time of their transplant, three (18{\%}) were on oral hypoglycemic agents alone and 14 (82{\%}) were on insulin therapy. Of the 17 transplants, seven (41{\%}) were a simultaneous pancreas-kidney transplant (SPK); four (24{\%}), pancreas after kidney transplant (PAK); and six (35{\%}), pancreas transplant alone (PTA). One recipient died during the perioperative period because of aspiration. The other 16 recipients became euglycemic post-transplant and had a functional graft at 1 yr post-transplant (patient and graft survival rates, 94{\%}). Now, with a mean follow-up of 4.3 yr post-transplant, the patient survival rate is 71{\%}. The four additional deaths were because of sepsis (n = 2), suicide (n = 1), and unknown cause (n = 1). All four of these recipients were insulin-independent at the time of death, although one was on an oral hypoglycemic agent. Of the 12 recipients currently alive, 11 remain euglycemic without requiring insulin therapy or oral hypoglycemic agents; one began insulin therapy 1.2 yr post-transplant (current daily dose, 60 units). Conclusion: These findings suggest that pancreas transplants can provide excellent glucose control in recipients with type 2 DM. All 16 (94{\%}) of our recipients whose transplant was technically successful were rendered euglycemic. Long-term results were comparable with those seen in transplant recipients with type 1 DM.",
keywords = "Pancreas transplants, Surgical complications, Type 2 diabetes mellitus",
author = "Nath, {Dilip S.} and Gruessner, {Angelika C} and Raja Kandaswamy and Gruessner, {Rainer W G} and Sutherland, {David E R} and Abhinav Humar",
year = "2005",
month = "12",
doi = "10.1111/j.1399-0012.2005.00423.x",
language = "English (US)",
volume = "19",
pages = "792--797",
journal = "Clinical Transplantation",
issn = "0902-0063",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Outcomes of pancreas transplants for patients with type 2 diabetes mellitus

AU - Nath, Dilip S.

AU - Gruessner, Angelika C

AU - Kandaswamy, Raja

AU - Gruessner, Rainer W G

AU - Sutherland, David E R

AU - Humar, Abhinav

PY - 2005/12

Y1 - 2005/12

N2 - Background: The objective of this study was to examine how effectively pancreas transplants provide long-term glucose control in patients with type 2 diabetes mellitus (DM). We used guidelines from the American Diabetes Association (ADA) and the World Health Organization (WHO) to appropriately classify recipients with type 2 DM (vs. type 1 DM). Results: From 1994 through 2002, a total of 17 patients with type 2 DM underwent a pancreas transplant at our center. Mean recipient age was 52.5 yr. The mean age at diabetes onset was 35.7 yr; mean duration, 16.8 yr. Most recipients had one or more secondary complications related to their diabetes: retinopathy (94%), neuropathy (76%), or nephropathy (65%). At the time of their transplant, three (18%) were on oral hypoglycemic agents alone and 14 (82%) were on insulin therapy. Of the 17 transplants, seven (41%) were a simultaneous pancreas-kidney transplant (SPK); four (24%), pancreas after kidney transplant (PAK); and six (35%), pancreas transplant alone (PTA). One recipient died during the perioperative period because of aspiration. The other 16 recipients became euglycemic post-transplant and had a functional graft at 1 yr post-transplant (patient and graft survival rates, 94%). Now, with a mean follow-up of 4.3 yr post-transplant, the patient survival rate is 71%. The four additional deaths were because of sepsis (n = 2), suicide (n = 1), and unknown cause (n = 1). All four of these recipients were insulin-independent at the time of death, although one was on an oral hypoglycemic agent. Of the 12 recipients currently alive, 11 remain euglycemic without requiring insulin therapy or oral hypoglycemic agents; one began insulin therapy 1.2 yr post-transplant (current daily dose, 60 units). Conclusion: These findings suggest that pancreas transplants can provide excellent glucose control in recipients with type 2 DM. All 16 (94%) of our recipients whose transplant was technically successful were rendered euglycemic. Long-term results were comparable with those seen in transplant recipients with type 1 DM.

AB - Background: The objective of this study was to examine how effectively pancreas transplants provide long-term glucose control in patients with type 2 diabetes mellitus (DM). We used guidelines from the American Diabetes Association (ADA) and the World Health Organization (WHO) to appropriately classify recipients with type 2 DM (vs. type 1 DM). Results: From 1994 through 2002, a total of 17 patients with type 2 DM underwent a pancreas transplant at our center. Mean recipient age was 52.5 yr. The mean age at diabetes onset was 35.7 yr; mean duration, 16.8 yr. Most recipients had one or more secondary complications related to their diabetes: retinopathy (94%), neuropathy (76%), or nephropathy (65%). At the time of their transplant, three (18%) were on oral hypoglycemic agents alone and 14 (82%) were on insulin therapy. Of the 17 transplants, seven (41%) were a simultaneous pancreas-kidney transplant (SPK); four (24%), pancreas after kidney transplant (PAK); and six (35%), pancreas transplant alone (PTA). One recipient died during the perioperative period because of aspiration. The other 16 recipients became euglycemic post-transplant and had a functional graft at 1 yr post-transplant (patient and graft survival rates, 94%). Now, with a mean follow-up of 4.3 yr post-transplant, the patient survival rate is 71%. The four additional deaths were because of sepsis (n = 2), suicide (n = 1), and unknown cause (n = 1). All four of these recipients were insulin-independent at the time of death, although one was on an oral hypoglycemic agent. Of the 12 recipients currently alive, 11 remain euglycemic without requiring insulin therapy or oral hypoglycemic agents; one began insulin therapy 1.2 yr post-transplant (current daily dose, 60 units). Conclusion: These findings suggest that pancreas transplants can provide excellent glucose control in recipients with type 2 DM. All 16 (94%) of our recipients whose transplant was technically successful were rendered euglycemic. Long-term results were comparable with those seen in transplant recipients with type 1 DM.

KW - Pancreas transplants

KW - Surgical complications

KW - Type 2 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=28644442484&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28644442484&partnerID=8YFLogxK

U2 - 10.1111/j.1399-0012.2005.00423.x

DO - 10.1111/j.1399-0012.2005.00423.x

M3 - Article

C2 - 16313327

AN - SCOPUS:28644442484

VL - 19

SP - 792

EP - 797

JO - Clinical Transplantation

JF - Clinical Transplantation

SN - 0902-0063

IS - 6

ER -